The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
A New Class of Fluorinated A2A Adenosine Receptor Agonist with Application to Last‐Step Enzymatic [18F]Fluorination for PET Imaging
Abstract
The A 2A adenosine receptor belongs to a family of G‐coupled protein receptors that have been subjected to extensive investigation over the last few decades. Due to their prominent role in the biological functions of the heart, lungs, CNS and brain, they have become a target for the treatment of illnesses ranging from cancer immunotherapy to Parkinson's disease. The imaging of such receptors by using positron emission tomography (PET) has also been of interest, potentially providing a valuable tool for analysing and diagnosing various myocardial and neurodegenerative disorders, as well as offering support to drug discovery trials. Reported herein are the design, synthesis and evaluation of two new 5′‐fluorodeoxy‐adenosine (FDA)‐based receptor agonists (FDA‐PP1 and FDA‐PP2), each substituted at the C‐2 position with a terminally functionalised ethynyl unit. The structures enable a synthesis of 18 F‐labelled analogues by direct, last‐step radiosynthesis from chlorinated precursors using the fluorinase enzyme (5′‐fluoro‐5′‐deoxyadenosine synthase), which catalyses a transhalogenation reaction. This delivers a new class of A 2A adenosine receptor agonist that can be directly radiolabelled for exploration in PET studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, fluorinase has been successfully leveraged in biosynthetic pathways to produce a variety of simple organofluorines used as PET tracers and medical imaging agents58–60.”
From The link between ancient microbial fluoride resistance mechanisms and bioengineering organofluorine degradation or synthesis (2024) · cites this paper as [59]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationThe 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
Jaakola, V., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y. T., Lane, J. R., IJzerman, A. P., & Stevens, R. C. (2008) · Science · doi:10.1126/science.1164772 · Cited by 1,819
Self-citationDrury, A. N., & Szent‐Györgyi, A. (1929) · The Journal of Physiology · doi:10.1113/jphysiol.1929.sp002608 · Cited by 1,510
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431
Calker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
Self-citationAdenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J. M., Cronstein, B. N., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,271
Enzyme-Catalyzed Phosphoryl Transfer Reactions
Knowles, J. R. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.004305 · Cited by 1,154
Adenosine receptors as drug targets — what are the challenges?
Chen, J., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 929
Structure of an Agonist-Bound Human A 2A Adenosine Receptor
Xu, F., Wu, H., Katritch, V., Han, G. W., Jacobson, K. A., Gao, Z., Cherezov, V., & Stevens, R. C. (2011) · Science · doi:10.1126/science.1202793 · Cited by 822
Purinergic Signaling during Inflammation
Eltzschig, H. K., Sitkovsky, M. V., & Robson, S. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1205750 · Cited by 739
Purinergic Signaling during Inflammation
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1300259 · Cited by 608
Fluorine-18 Radiochemistry, Labeling Strategies and Synthetic Routes
Jacobson, O., Kiesewetter, D. O., & Chen, X. (2015) · Bioconjugate Chemistry · doi:10.1021/bc500475e · Cited by 503
Biosynthesis of an organofluorine molecule
O’Hagan, D., Schaffrath, C., Cobb, S. L., Hamilton, J. T. G., & Murphy, C. D. (2002) · Nature · doi:10.1038/416279a · Cited by 450
Self-citationRecent developments in adenosine receptor ligands and their potential as novel drugs
Müller, C. E., & Jacobson, K. A. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.017 · Cited by 431
Effect of γ-butyrobetaine on fatty liver in juvenile visceral steatosis mice
Higashi, Y., Yokogawa, K., Takeuchi, N., Tamai, I., Nomura, M., Hashimoto, N., Hayakawa, J.-I., Miyamoto, K.-I., & Tsuji, A. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011775631 · Cited by 373
ACTIONS OF ADENOSINE AT ITS RECEPTORS IN THE CNS: Insights from Knockouts and Drugs
Fredholm, B. B., Chen, J., Masino, S. A., & Vaugeois, J. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095731 · Cited by 365
Adenosine A 2A Receptor as a Drug Discovery Target
de Lera Ruiz, M., Lim, Y.-H., & Zheng, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4011669 · Cited by 276
CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity.
Hutchison, A. J., Webb, R. L., Oei, H. H., Ghai, G. R., Zimmerman, M. B., & Williams, M. J. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20735-2 · Cited by 247
Adenosine A2A and Dopamine D2 Heteromeric Receptor Complexes and Their Function
Fuxe, K., Ferré, S., Canals, M., Torvinen, M., Terasmaa, A., Marcellino, D., Goldberg, S. R., Staines, W., Jacobsen, K. X., Lluis, C., et al. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:26:2-3:209 · Cited by 235
Structure-Based Discovery of A 2A Adenosine Receptor Ligands
Carlsson, J., Yoo, L. S., Gao, Z.-G., Irwin, J. J., Shoichet, B. K., & Jacobson, K. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100240h · Cited by 233
Brain Imaging of Nicotinic Receptors in Alzheimer's Disease
Wu, J., Ishikawa, M., Zhang, J., & Hashimoto, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/548913 · Cited by 211
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
Armentero, M., Pinna, A., Ferré, S., Lanciego, J. L., Müller, C. E., & Franco, R. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.07.004 · Cited by 197
Gutiérrez‐de‐Terán, H., Massink, A., Rodriguez, D. J., Liu, W., Han, G. W., Joseph, J. S., Katritch, I., Heitman, L. H., Xia, L., IJzerman, A. P., et al. (2013) · Structure · doi:10.1016/j.str.2013.09.020 · Cited by 139
Self-citationAdenosine receptors and their modulators
Müller, C. E., & Scior, T. (1993) · Pharmaceutica Acta Helvetiae · doi:10.1016/0031-6865(93)90012-u · Cited by 126
Allosteric modulation of A2A adenosine receptors by amiloride analogues and sodium ions
Gao, Z., & IJzerman, A. P. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00360-9 · Cited by 106
Self-citationA2A Adenosine Receptors on Bone Marrow-Derived Cells Protect Liver from Ischemia-Reperfusion Injury
Day, Y., Li, Y., Rieger, J. M., Ramos, S. I., Okusa, M. D., & Linden, J. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.5040 · Cited by 96
Design, Synthesis, and Evaluation of Novel A2A Adenosine Receptor Agonists
Rieger, J. M., Brown, M. L., Sullivan, G. W., Linden, J. M., & Macdonald, T. L. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0003642 · Cited by 88
Cavalcante, I. C., Castro, M. V., Barreto, A. R. F., Sullivan, G. W., Vale, M. L., de Almeida, P. R. C., Linden, J. M., Rieger, J. M., Cunha, F. Q., Guerrant, R. L., et al. (2006) · Infection and Immunity · doi:10.1128/iai.74.5.2606-2612.2006 · Cited by 72
Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury
Gazoni, L. M., Walters, D. M., Unger, E. B., Linden, J. M., Kron, I. L., & Laubach, V. E. (2010) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.03.002 · Cited by 63
Thompson, S., Zhang, Q., Onega, M., McMahon, S. A., Fleming, I. N., Ashworth, S., Naismith, J. H., Passchier, J., & O’Hagan, D. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403345 · Cited by 58
Self-citationCharacterization in Humans of 18F-MNI-444, a PET Radiotracer for Brain Adenosine 2A Receptors
Barret, O., Hannestad, J. O., Vala, C., Alagille, D., Tavares, A., Laruelle, M. A., Jennings, D. L., MAREK, K. L., Russell, D., Seibyl, J. P., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.152546 · Cited by 53
Moore, C. C., Martin, E. N., Lee, G. H., et al. (2008) · BMC Infectious Diseases · doi:10.1186/1471-2334-8-141 · Cited by 51
PET Tracers for Mapping Adenosine Receptors as Probes for Diagnosis of CNS Disorders
Ishiwata, K., Kimura, Y., de Vries, E. F. J., & Elsinga, P. H. (2007) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152407780059259 · Cited by 29
Adenosine Receptor PET Imaging in Human Brain
Mishina, M., & Ishiwata, K. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00002-7 · Cited by 29
Zhang, Q., Dall’Angelo, S., Fleming, I. N., Schweiger, L. F., Zanda, M., & O’Hagan, D. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201601361 · Cited by 27
Self-citationHothersall, J. D., Guo, D. M., Sarda, S., Sheppard, R. J., Chen, H., Keur, W., Waring, M. J., IJzerman, A. P., Hill, S. J., Dale, I. L., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105551 · Cited by 26
Self-citationProbing the molecular determinants of fluorinase specificity
Yeo, W. L., Chew, X., Smith, D. J., Chan, K. P., Sun, H., Zhao, H., Lim, Y. H., & Ang, E. L. (2017) · Chemical Communications · doi:10.1039/c6cc09213f · Cited by 25
Adenosine A2A Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Khanapur, S., van Waarde, A., Ishiwata, K., Leenders, K. L., Dierckx, R. A. J. O., & Elsinga, P. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113206660265 · Cited by 24
Basu, S., Barawkar, D. A., Thorat, S., Shejul, Y. D., Patel, M., Naykodi, M., Jain, V. K., Salve, Y., Prasad, V., Chaudhary, S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01584 · Cited by 22
Thompson, S., Zhang, Q., Onega, M., McMahon, S. A., Fleming, I. N., Ashworth, S., Naismith, J. H., Passchier, J., & O’Hagan, D. (2014) · Angewandte Chemie · doi:10.1002/ange.201403345 · Cited by 18
Self-citationEnzymatic transhalogenation of dendritic RGD peptide constructs with the fluorinase
Thompson, S., Fleming, I. N., & O’Hagan, D. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00239k · Cited by 16
Self-citationSaku, O., Saki, M., Kurokawa, M., Ikeda, K., Uchida, S., Takizawa, T., & Uesaka, N. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.058 · Cited by 16
Dai, W., Hale, S. L., Nayak, R., & Kloner, R. A. (2009) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192400903010166 · Cited by 9
Noël, F., & do Monte, F. M. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.10.009 · Cited by 6
Research works printed but not linked: 1
- Heiss W. D., 2006, J. Nucl. Med., 47, 302
Cited by
Stockbridge, R. B., & Wackett, L. P. (2024) · Nature Communications · doi:10.1038/s41467-024-49018-1 · Cited by 80
Metadata
- Authors
- Lowe, P. T., Dall'Angelo, S., Mulder‐Krieger, T., IJzerman, A. P., Zanda, M., & O'Hagan, D.
- Venue
- ChemBioChem
- Publisher
- Wiley
- Published
- 2017-09-21
- Volume
- 18
- Issue
- 21
- Pages
- 2156-2164
- ISSN
- 1439-4227
- 1439-7633
- Cited by
- 19
- References
- 45
- Language
- en
- Funders
- Engineering and Physical Sciences Research Council (EP/M01262X/1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
